Stock comparison
Globus Medical
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMED
Globus Medical
Market cap
$11.44B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMED | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 75B | IDXX |
| Benjamin Graham | 65B | 80A | IDXX |
| Philip Fisher | 70C | 75B | IDXX |
| Peter Lynch | 63C | 71B | IDXX |
| Joel Greenblatt | 45D | 83C | IDXX |
| Charlie Munger | 51D | 87A | IDXX |
| Terry Smith | 56D | 84A | IDXX |
Side-by-side metrics
| Metric | GMED | IDXX |
|---|---|---|
| Market cap | $11.44B | $44.12B |
| P/E (TTM) | 17.7x | 39.0x |
| EV/EBIT | 20.6x | 31.6x |
| ROIC (TTM) | 9.72% | 40.66% |
| Gross margin | 67.86% | 62.05% |
| Net margin | 18.92% | 24.63% |
| Revenue CAGR 5y | 32.34% | 7.56% |
| EPS CAGR 5y | 28.06% | 10.79% |
| Debt / Equity | 0.0x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMED leads on
- Debt / Equity0.0xvs 0.7x+96%
- Revenue CAGR 5y32.34%vs 7.56%+77%
- EPS CAGR 5y28.06%vs 10.79%+62%
- P/E (TTM)17.7xvs 39.0x+55%
IDXX leads on
- ROIC (TTM)40.66%vs 9.72%+76%
- Market cap$44.12Bvs $11.44B+74%
- Net margin24.63%vs 18.92%+23%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.